Divi’s Laboratories | Business Upturn

Top Q3 Results Today, Feb 11: M&M, Divi’s Laboratories, Ashok Leyland, IRCON, Godrej Industries and more to announce earnings

Aman Shukla — Wed, 11 Feb 2026 02:40:07 +0000

Several Indian companies across sectors such as automobiles, pharmaceuticals, food processing, infrastructure, and others are scheduled to announce their Q3 (October-December 2025) financial results on February 11, 2026. These announcements cover the third quarter of FY 2025-26.

Major Companies in Focus

Mahindra & Mahindra (M&M): Automobile sector player, known for SUVs and tractors.
Divi’s Laboratories: Pharmaceutical company specializing in active pharmaceutical ingredients (APIs) and custom synthesis.
Ashok Leyland: Commercial vehicle manufacturer.
LG Electronics India: Consumer electronics and home appliances.
Lenskart (Lenskart Solutions): Eyewear and vision care provider.
Patanjali Foods: Food processing and FMCG.
Protean eGov Technologies: Government-related digital services.
SJVN: Hydroelectric power generation.
Jupiter Wagons: Railway wagon manufacturing.
IRCON International: Engineering and construction in railways and infrastructure.
Godrej Industries: Conglomerate with interests in chemicals and other sectors.
AstraZeneca Pharma: Pharmaceutical firm.
Bayer CropScience: Crop protection and agriculture solutions.
Avanti Feeds: Aquaculture and shrimp exports.
Max Financial Services: Insurance and financial services.
Orkla India: FMCG products.

Additional Companies Announcing Results

Other firms include:

Apex Frozen Foods
Bombay Dyeing
Capacite Infra
Carraro India
Dollar Industries
Dwarikesh Sugar
IOL Chemicals
JTEKT India
Linc
Neogen Chemicals
NOCIL
Orchid Pharma
Surya Roshni
Talbros Automotive

Divi’s Laboratories clears USFDA inspection at Telangana facility with zero 483 observations

Aman Shukla — Fri, 14 Nov 2025 10:31:22 +0000

Divi’s Laboratories has reported a positive regulatory development, confirming that the US Food and Drug Administration (USFDA) has successfully completed a comprehensive cGMP inspection at the company’s Unit-I facility located in Lingojigudem Village, Choutuppal Mandal, Yadadri Bhuvanagiri district in Telangana. The inspection was conducted over five days, from November 10 to November 14, 2025.

What makes this update significant is that the audit concluded with zero Form 483 observations. In regulatory terms, this indicates that the USFDA inspectors did not find any deviations from current Good Manufacturing Practices (cGMP). For a pharmaceutical manufacturer, such an outcome strongly reinforces the company’s quality systems, compliance culture, and operational standards.

A clean USFDA inspection is especially important for companies like Divi’s Laboratories, which supply active pharmaceutical ingredients (APIs) and intermediates to global markets. With no 483s issued, the company not only strengthens its regulatory track record but also boosts confidence among international partners, customers and investors.

This development is expected to be seen as a positive sign for future approvals, export momentum and overall business stability.

Divi’s Laboratories Q2 Results: Revenue jumps 16% YoY to Rs 2,715 crore, net profit up 35%

Aman Shukla — Fri, 07 Nov 2025 06:39:03 +0000

Divi’s Laboratories Limited announced its consolidated unaudited financial results for the quarter ended 30 September 2025, showcasing a healthy performance both in revenue and profitability compared to the same quarter last year.

For Q2 FY2025, the company reported a revenue from operations of ₹2,715 crore, marking a 15.9% increase from ₹2,338 crore recorded in Q2 FY2024. The growth was driven by improved exports and steady demand in the custom synthesis segment.

The total income for the quarter rose to ₹2,860 crore, up 17% YoY from ₹2,444 crore in the corresponding quarter of the previous year.

Operating performance remained solid with EBITDA rising 24% year-on-year to ₹888 crore against ₹716 crore in the corresponding quarter of the previous year. The EBITDA margin improved to 32.7% from 30.6%.

The profit before tax (PBT) came in at ₹912 crore, up 26.3% YoY from ₹722 crore in Q2 FY2024. After accounting for taxes of ₹223 crore, the net profit stood at ₹689 crore, a sharp 35.1% jump YoY over ₹510 crore in the same quarter last year.

Top Q2 results today, November 7: Bajaj Auto, Hindalco Industries, Divi’s Laboratories, Trent, Nykaa and more to announce earnings

Aman Shukla — Fri, 07 Nov 2025 02:39:56 +0000

The Indian stock market will witness a major wave of quarterly earnings announcements, with around 180 listed companies scheduled to release their Q2 FY2025 results. The day’s lineup includes some of India’s top names across sectors such as auto, metals, pharma, retail, energy, and finance.

Among the key companies set to declare their earnings today are Bajaj Auto, Hindalco Industries, Divi’s Laboratories, Trent, Nykaa (FSN E-Commerce Ventures), and Kalyan Jewellers India.

Here’s the complete list of companies declaring Q2 results on Friday, November 7, 2025:

Bajaj Auto, Divis Laboratories, Hindalco Industries, Trent, Power Finance Corporation, Torrent Pharmaceuticals, UNO Minda, FSN E-Commerce Ventures (Nykaa), Kalyan Jewellers India, National Aluminium Company, Petronet LNG, Cholamandalam Financial Holdings, Global Health, AIA Engineering, Krishna Institute of Medical Sciences, Aegis Logistics, Force Motors, Shyam Metalics & Energy, AstraZeneca Pharma, Neuland Laboratories, Aadhar Housing Finance, Bayer CropScience, Schneider Electric Infrastructure, JSW Cement, NAVA, Ratnamani Metals and Tubes, SignatureGlobal India, Great Eastern Shipping Company, Trident, Fine Organics Industries, Shipping Corporation of India, Finolex Industries, IIFL Capital Services, Jupiter Life Line Hospitals, KPI Green Energy, Shakti Pumps (India), Sandur Manganese and Iron Ores, Birla Corporation, Va Tech Wabag, Arvind, Lloyds Engineering Works, Garware Technical Fibres, Prism Johnson, Aditya Vision, Piccadily Agro Industries, Puravankara, Skipper, Innova Captab, Lumax Industries, Bannariamman Sugars, WPIL, Aarti Drugs, Gujarat Alkalies and Chemicals, SpiceJet, Borosil, Pitti Engineering, Go Fashion India, Prince Pipes & Fittings, Sanghvi Movers, Kiri Industries, Deep Industries, S H Kelkar & Company, KP Green Engineering, Marsons, K.P. Energy, Kovai Medical Center and Hospital, ADF Foods Industries, Krsnaa Diagnostics, Rashi Peripherals, Venkys, Sasken Technologies, Ugro Capital, Somany Ceramics, Paushak, IKIO Technologies, Centrum Capital, V-Marc India, The Hi-Tech Gears, Birla Nuvo (BIRLANU), Arisinfra Solutions, STL Networks, Ashika Credit Capital, SBC Exports, Saurashtra Cement, Mamata Machinery, Zuari Agro Chemicals, Concord Enviro Systems, Allied Digital Services, Fairchem Organics, Kuantum Papers, Anuh Pharma, Krystal Integrated Services, A.K. Capital Services, 20 Microns, Credo Brands Marketing, Commercial Syn Bags, Shree Ganesh Remedies, Veljan Denison, Batliboi, CL Educate, Forbes Gokak, Pasupati Acrylon, Khadim India, Ludlow Jute & Specialities, Inspirisys Solutions, Indag Rubber, Capital Trade Links, U.Y. Fincorp, Radix Industries (India), Revathi Equipment India, United Van Der Horst, Oxygenta Pharmaceutical, Sheetal Cool Products, KPT Industries, Mach Conferences & Events, Tips Films, Parshva Enterprises, Ecoplast, Bharat Gears, Apollo Finvest (India), BD Industries Pune, Bansal Roofing Products, Remi Edelstahl Tubulars, Naturite Agro Products, Siddhika Coatings, Kemp and Company, BA Packaging India, Aksh Optifibre, Shetron, Shervani Industrial Syndicate, Continental Petroleums, FYNX Capital, Alkali Metals, Sonu Infratech, APM Industries, Makers Laboratories, Raj Oil Mills, Biogen Pharmachem Industries, Ram Informatics, Everlon Financials, Ansal Properties & Infrastructure, Perfectpac, Bridge Securities, Sita Enterprises, 21st Century Management, Polylink Polymers (India), Indus Finance, Manoj Jewellers, Akshar Spintex, Patspin India, SER Industries, Ind Cement Cap, Chandra Prabhu International, Cella Space Limited, Global Capital Markets, Virtual Global Education, Satchmo Holdings, GTN Textiles, Bharat Bhushan Finance and Commodity Brokers, and Olympia Industries.

Divi’s Laboratories shares drop 3% as Q1 misses estimates

Aman Shukla — Wed, 06 Aug 2025 06:41:57 +0000

Divi’s Laboratories shares came under pressure, falling more than 3% after the company’s Q1 FY26 results fell short of street expectations. As of 12:12 PM, the shares were trading 2.74% lower at Rs 6,233.50.

For the quarter ended June 30, 2025, Divi’s posted a net profit of ₹545 crore, below the CNBC-TV18 poll estimate of ₹573 crore, though it marked a 26.7% rise from ₹430 crore in Q1 FY25. Revenue from operations came in at ₹2,410 crore, up 13.8% YoY, but also shy of the expected ₹2,437 crore.

On the operational front, EBITDA stood at ₹756 crore, registering a 16.3% YoY growth, but again missed estimates pegged at ₹794.8 crore. EBITDA margin improved to 31.4% from 30.7% a year ago, though fell short of the 32.6% projection.

Sequentially, however, numbers were softer — revenue declined 6.8%, and net profit fell nearly 18% versus Q4 FY25.

Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.

Divi’s Laboratories Q1 Results: Revenue jumps 13.8% YoY to Rs 2,410 crore, net profit up 26.7% YoY

Aman Shukla — Wed, 06 Aug 2025 06:27:46 +0000

Divi’s Laboratories posted its financial results for the quarter ended June 30, 2025 (Q1 FY26), showcasing a strong year-on-year (YoY) growth in profitability even as revenue slipped marginally on a sequential basis.

For Q1 FY26, Divi’s reported revenue from operations at ₹2,410 crore, marking a 13.8% increase from ₹2,118 crore in Q1 FY25. However, when compared to the previous quarter (Q4 FY25), revenue dipped by around 6.8% from ₹2,585 crore.

The company’s net profit for the quarter stood at ₹545 crore, showing a 26.7% YoY growth from ₹430 crore in the same quarter last year. On a quarter-on-quarter (QoQ) basis, net profit declined by 17.7% from ₹662 crore in Q4 FY25.

EBITDA for the quarter rose 16.3% year-on-year to ₹756 crore, compared to ₹650 crore in Q1 FY25. EBITDA margin also improved, coming in at 31.4% versus 30.7% a year ago.

The company’s total expenses for the quarter stood at ₹1,796 crore, up from ₹1,593 crore a year ago. The cost of materials consumed rose 13% year-on-year to ₹1,010 crore, while employee expenses grew to ₹340 crore from ₹292 crore in the previous year’s first quarter.

Top Q1 results today, August 6: Bajaj Auto, Hero MotoCorp, Trent, Divi’s Laboratories, BHEL and more to announce earnings

Aman Shukla — Wed, 06 Aug 2025 02:41:57 +0000

A busy earnings day lies ahead on Wednesday, August 6, 2025, as several Indian companies are set to report their financial results for the quarter ended June 2025 (Q1 FY26).

Among the key names to watch are Bajaj Auto, Hero MotoCorp, and Trent, which operates the popular fashion retail chain Zudio. Pharma player Divi’s Laboratories, financial services firm Bajaj Holdings & Investment, and adhesives major Pidilite Industries are also on the list.

Other companies scheduled to release Q1 earnings include Power Finance Corporation (PFC), Bharat Heavy Electricals Ltd (BHEL), Fortis Healthcare, and Raymond Ltd.

Here is the full list of companies expected to announce their Q1 FY26 results on August 6:

Bajaj Auto Ltd
Divis Laboratories Ltd
Trent Ltd
Hero MotoCorp Ltd
Bajaj Holdings & Investment Ltd
Pidilite Industries Ltd
Power Finance Corporation Ltd
Bharat Heavy Electricals Ltd
Fortis Healthcare Ltd
UNO Minda Ltd
Bharat Forge Ltd
Housing & Urban Development Corporation Ltd (HUDCO)
KPR Mill Ltd
Blue Star Ltd
Jindal Stainless Ltd
Krishna Institute of Medical Sciences Ltd
Bayer CropScience Ltd
SKF India Ltd
Jyoti CNC Automation Ltd
EID Parry (India) Ltd
Godrej Agrovet Ltd
Kirloskar Oil Engines Ltd
RITES Ltd
Ircon International Ltd
Sundaram Finance Holdings Ltd
PVR INOX Ltd
Cera Sanitaryware Ltd
Gujarat Narmada Valley Fertilizers & Chemicals Ltd (GNFC)
TD Power Systems Ltd
Raymond Lifestyle Ltd
Electrosteel Castings Ltd
Welspun Enterprises Ltd
VIP Industries Ltd
Datamatics Global Services Ltd
Rain Industries Ltd
VRL Logistics Ltd
Hawkins Cooker Ltd
Bannariamman Sugars Ltd
NIIT Learning Systems Ltd
Gopal Snacks Ltd
Raymond Ltd
Sundaram-Clayton Ltd
Indraprastha Medical Corporation Ltd
Harsha Engineers International Ltd
Prince Pipes & Fittings Ltd
Lumax Industries Ltd
Balmer Lawrie & Co Ltd
Morepen Laboratories Ltd
Protean eGov Technologies Ltd
Windsor Machines Ltd
Tasty Bite Eatables Ltd
Hinduja Global Solutions Ltd
Ravindra Energy Ltd
Afcom Holdings Ltd
Sula Vineyards Ltd
Sanghvi Movers Ltd
Shipping Corporation of India Land and Assets Ltd
Tinna Rubber and Infrastructure Ltd
MM Forgings Ltd
GPT Healthcare Ltd
Tribhovandas Bhimji Zaveri Ltd
Peninsula Land Ltd
Linc Ltd
Monte Carlo Fashions Ltd

Divi’s Laboratories shares fall 3% after MSN wins Entresto patent case

Aman Shukla — Mon, 14 Jul 2025 03:48:26 +0000

Shares of Divi’s Laboratories fell 3% in early trade after MSN Laboratories secured a win in a key patent litigation case involving Novartis’s blockbuster heart failure drug Entresto (Sacubitril/Valsartan). The legal victory now opens the door for MSN to launch a generic version in the U.S. after July 15, 2025.

The development could be a setback for Divi’s, which is believed to be a major API (Active Pharmaceutical Ingredient) supplier for Entresto through its Custom Synthesis (CS) business. Brokerage firm Motilal Oswal noted that Entresto is likely the largest product in Divi’s innovator CS portfolio. With MSN’s generic entry, Divi’s may face an annual revenue loss of up to $100 million, which equates to about 5% of its total revenue.

However, the potential impact may already be baked into the company’s outlook. According to Motilal Oswal’s note, Divi’s had earlier indicated that changes in the product’s lifecycle were expected, likely referring to warnings from the innovator about patent expiry timelines.

Divi’s Laboratories share hits new 52-week high as HSBC upgrades to ‘Buy’, raises target price to Rs 7,900

Aman Shukla — Tue, 08 Jul 2025 03:56:08 +0000

Divi’s Laboratories shares surged to a new 52-week high of ₹7,071.50 on July 8 after HSBC upgraded the stock to Buy and sharply raised its target price to ₹7,900 from ₹5,020.

HSBC’s bullish stance is driven by a strong medium-term outlook, with significant revenue potential from high-growth segments like tirzepatide, other peptides, and contrast media. The brokerage estimates around USD 450 million in peptide revenue and USD 260 million from contrast media by 2030.

Citing Divi’s leadership in custom synthesis and complex API manufacturing, HSBC projects a 23% CAGR in earnings per share for FY25–28. The firm sees Divi’s benefiting from the global trend of outsourcing complex molecules, boosting profitability and margins over time.

The stock opened at ₹7,002 and hit an intraday low of ₹6,972.50 before climbing to its fresh peak. Divi’s Laboratories’ previous 52-week low stood at ₹4,395.30.

Stocks hitting 52-week highs today, July 2: Divi’s Laboratories, Bharti Airtel, UltraTech Cement, Dalmia Bharat and more

Aman Shukla — Wed, 02 Jul 2025 10:15:39 +0000

Despite broader market weakness on July 2, several stocks managed to hit their 52-week highs, signalling strong investor interest. The Sensex slipped 287.60 points to close at 83,409.69, while the Nifty ended 88.40 points lower at 25,453.40. However, the following stocks stood out by touching fresh 52-week highs during the session.

Key Stocks That Hit 52-Week Highs Today (July 2)

Company	Market Price (₹)	52-Week High (₹)
Divi’s Laboratories	6,859.50 (+0.04%)	6,885.50
Bharti Airtel	2,033.30 (+0.69%)	2,045.80
Laurus Labs	756.75 (+1.43%)	761.75
UltraTech Cement	12,436.00 (+1.85%)	12,527.00
SRF	3,255.60 (+1.74%)	3,281.60
JK Lakshmi Cement	986.00 (+3.56%)	995.00
Federal Bank	217.75 (-0.44%)	220.00
LT Foods	494.75 (+3.95%)	500.00
Dalmia Bharat	2,220.10 (+1.43%)	2,245.00
Ramco Cements	1,088.40 (+1.04%)	1,101.90
Asahi India Glass	830.55 (+3.01%)	842.00
L&T Finance	206.22 (-0.78%)	209.60
AU Small Finance Bank	818.25 (-2.40%)	841.00
KRBL	379.50 (+1.12%)	390.40
Gabriel India	976.20 (+15.84%)	1,011.30
Cholamandalam Financial Holdings	2,148.80 (+1.74%)	2,231.60
South Indian Bank	31.04 (-1.77%)	32.25
Fiem Industries	1,923.30 (-0.77%)	1,999.00
City Union Bank	221.44 (-3.93%)	232.55
Sai Life Sciences	789.10 (+1.19%)	838.50

Divi’s Laboratories shares in focus after Novartis and MSN settle on Entresto 659 patent

Aman Shukla — Wed, 18 Jun 2025 03:59:24 +0000

Shares of Divi’s Laboratories are in focus after an update in the legal proceedings surrounding Novartis’ heart failure drug Entresto. Novartis and MSN Laboratories have reached a settlement on the ‘659 patent, which was one of the key patents protecting Entresto.

With this settlement, attention now shifts to the next patent in the litigation timeline. The subsequent patent is set to expire in November 2026, with associated regulatory exclusivity extending until May 2027.

According to analysts, this development could lead to potential upward revisions in Divi’s financial estimates for FY26 and FY27, depending on how the litigation progresses and market dynamics evolve in the coming quarters.

Divi’s Laboratories shares traded in a narrow range today, opening at ₹6,548 and, at the time of writing, reached an intraday high of ₹6,640.50. The stock touched a low of ₹6,513 during the session. It remains close to its 52-week high of ₹6,862.50, while the 52-week low stands at ₹4,395.30.

Divi’s Laboratories shares surge 3% on major global supply deal

Aman Shukla — Mon, 26 May 2025 03:47:21 +0000

Shares of Divi’s Laboratories jumped 3% after the company announced a long-term manufacturing and supply agreement with a leading global pharmaceutical firm. As of 9:18 AM, the shares were trading 3.59% higher at Rs 6,715.50.

This strategic move boosts Divi’s presence in the custom synthesis segment, reinforcing its position as a trusted contract manufacturing partner on the international stage.

Under the deal, Divi’s will manufacture and supply advanced pharmaceutical intermediates, a high-value segment that is expected to significantly enhance the company’s revenue over the duration of the contract. Although the partner’s identity and financial specifics remain under wraps due to a non-disclosure agreement, the company has indicated that the expected returns are substantial.

To meet the growing demand, Divi’s Laboratories is planning a capacity expansion investment of ₹650–750 crore, which will be funded through a phased capacity reservation advance from the customer. This ensures financial stability while scaling operations.

The company clarified that the agreement is entirely commercial with no related party involvement, highlighting its commitment to transparency and global business standards.

Divis Laboratories signs long-term supply deal with global pharma company

Aman Shukla — Sat, 24 May 2025 03:50:15 +0000

Divis Laboratories has recently informed exchanges that the company entered into a long-term manufacturing and supply agreement with a global pharmaceutical company. This international agreement marks a strategic move by Divis to strengthen its presence in the custom synthesis segment.

Under the terms of the agreement, Divis Laboratories will be responsible for manufacturing and supplying advanced intermediates. The arrangement is expected to contribute meaningfully to the company’s revenue over the duration of the contract. While specific financial figures and the identity of the partner company remain confidential due to a non-disclosure agreement, the company has indicated that the expected returns are significant.

To support the operations under this agreement, Divis plans to undertake capacity expansion with an estimated investment of ₹650–750 crore. This capital expenditure will be financed through a phased capacity reservation advance that the customer is expected to pay, as per the terms of the agreement.

The company emphasized that the agreement is strictly commercial in nature, with no related party transactions involved. The collaboration is aimed at ensuring a reliable supply chain for the customer while allowing Divis Laboratories to deepen its footprint in the global custom manufacturing market.

Divi’s Laboratories shares jump 5% as Q4 revenue rises 12% YoY to Rs 2,585 crore

Aman Shukla — Mon, 19 May 2025 03:50:59 +0000

Divi’s Laboratories Limited shares jumped nearly 5% in morning trade following the release of strong Q4 FY25 results.

The company reported a 23% year-on-year (YoY) rise in consolidated net profit to ₹662 crore for the quarter ended March 31, 2025, compared to ₹538 crore in Q4 FY24. The impressive growth was supported by higher sales and better operational efficiency.

Revenue from operations rose 12% YoY to ₹2,585 crore, up from ₹2,303 crore in the same period last year. Total income for the quarter stood at ₹2,671 crore, compared to ₹2,382 crore in Q4 FY24. The company’s EBITDA increased to ₹869 crore from ₹808 crore, with a stable EBITDA margin of 32.5%.

Despite a rise in total expenses to ₹1,807 crore, driven by higher material and employee costs, Divi’s posted a profit before tax of ₹864 crore—up from ₹713 crore a year ago.

For the full financial year FY25, Divi’s Laboratories reported a net profit of ₹2,191 crore, marking a robust 37% increase from ₹1,600 crore in FY24. Total income for the year rose to ₹9,712 crore from ₹8,184 crore.

In the meantime, Nuvama has reiterated a Buy on Divi’s Labs with a target of ₹7,225, implying a ~15% upside from the current price of ₹6,268. Strong Q4 margins and growth in API and nutraceuticals segments were key positives. Operations have begun at Unit-III (₹1,500 crore capex), and the GLP-1 intermediate opportunity could add $100–175 million annually upon commercialisation, as per Nuvama.

Divi’s Laboratories shares opened at ₹6,400 and surged to a high of ₹6,656, marking a new 52-week high. The stock also touched a low of ₹6,333.50 during the session. This performance reflects a significant uptrend, especially considering the 52-week low of ₹3,850.

Divi’s Laboratories Q4 Results: Revenue up 12% YoY to Rs 2,585 crore, Net profit jumps 23% YoY

Aditya Bhagchandani — Sat, 17 May 2025 07:54:19 +0000

Divi’s Laboratories Limited has reported a 23% year-on-year growth in its consolidated net profit at Rs 662 crore for the quarter ended March 31, 2025, compared to Rs 538 crore in the same quarter last year. The strong profit performance was driven by higher sales and improved operational efficiency.

Revenue from operations for the quarter rose 12% YoY to Rs 2,585 crore, up from Rs 2,303 crore in the corresponding quarter last year. Total income for the period increased to Rs 2,671 crore, compared to Rs 2,382 crore in the year-ago period.

The company’s EBITDA for the quarter stood at Rs 869 crore, reflecting a year-on-year increase from Rs 808 crore. The EBITDA margin improved to 32.5% in Q4 FY25, compared to 33.9% in the same quarter last year, indicating a stable operational performance.

Total expenses rose to Rs 1,807 crore from Rs 1,669 crore last year, led by higher material and employee costs. Profit before tax for the quarter was Rs 864 crore, up from Rs 713 crore in the same period a year ago.

For the full fiscal year FY25, Divi’s Laboratories reported a net profit of Rs 2,191 crore, a growth of 37% from Rs 1,600 crore posted in the previous year. Total income for the year was Rs 9,712 crore, compared to Rs 8,184 crore in FY24.

Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.

Divi’s Laboratories Q3 FY25 Results: Revenue up 25% YoY to Rs 2,319 crore, Net Profit up 64% YoY

Aditya Bhagchandani — Mon, 03 Feb 2025 07:43:10 +0000

Divi’s Laboratories Limited reported a strong set of financial results for Q3 FY25, with the company registering a profit of ₹589 crore, marking a significant 65% year-on-year (YoY) growth compared to ₹358 crore in the same quarter of the previous year. The impressive growth was driven by higher revenue and efficient cost management.

Key Highlights:

Revenue: The company’s revenue from operations for the quarter stood at ₹2,319 crore, a 25% YoY increase from ₹1,855 crore in Q3 FY24. Sequentially, revenue saw a slight dip compared to ₹2,338 crore in Q2 FY25.
Total Income: Including other income of ₹82 crore, the total income for the quarter amounted to ₹2,401 crore, compared to ₹1,950 crore in the year-ago period.
Expenses: Total expenses increased to ₹1,675 crore from ₹1,461 crore in Q3 FY24, driven mainly by a higher cost of materials consumed, which rose to ₹1,021 crore from ₹794 crore last year.
Profit Before Tax (PBT): PBT surged to ₹726 crore from ₹489 crore in Q3 FY24, reflecting strong operational performance.
Tax Expense: The company recorded a total tax expense of ₹137 crore during the quarter, down from ₹212 crore in the previous quarter.
Net Profit: The net profit of ₹589 crore is a result of improved operational efficiency and robust revenue growth.

Nine-Month Performance:

For the nine months ended December 31, 2024, the company reported:

Revenue from operations: ₹6,775 crore, compared to ₹5,542 crore in the previous year.
Net profit: ₹1,529 crore, a notable increase from ₹1,062 crore in the nine-month period of the previous fiscal.

Divi’s Laboratories begins commercial operations at Unit III greenfield project in Kakinada

Aman Shukla — Thu, 02 Jan 2025 09:54:30 +0000

Divi’s Laboratories Limited has recently informed exchanges that the company officially commenced commercial operations at part of Phase I of its Unit III greenfield project located in Ontimamidi Village, Kakinada, Andhra Pradesh, as of January 1, 2025. This milestone is a key development in the company’s ongoing expansion efforts.

The Unit III project is being developed on a 200-acre portion of the total 500-acre site, with an estimated investment ranging between ₹1,200 crores and ₹1,500 crores.

Due to delays in receiving final confirmation of commencement, the announcement is being made on January 2, 2025. The company looks forward to further progress in the coming months.

In the meantime, Divi’s Laboratories shares opened at ₹6,073.00, reaching a high of ₹6,154.75 and a low of ₹6,010.00. The stock has shown strong performance, with a 52-week high of ₹6,285.45 and a 52-week low of ₹3,350.00.

Divi’s Laboratories market cap rises by Rs 4,270 crore

Aditya Bhagchandani — Fri, 29 Nov 2024 06:13:41 +0000

Shares of Divi’s Laboratories surged by 2.70% today, reaching Rs 6,112.70. This price rally led to an increase in the company’s market capitalization by approximately Rs 4,270 crore, bringing it to a total of Rs 1,62,334.04 crore.

Key trading highlights:

Opening price: Rs 6,024.05
Day’s high: Rs 6,129.80
Day’s low: Rs 6,000.00
Volume traded: 3.92 lakh shares
Value traded: Rs 238.56 crore

Price information:

52-week high: Rs 6,275.85 (15-Oct-2024)
52-week low: Rs 3,350.00 (27-Mar-2024)
Daily volatility: 1.62%

Additional context:

Divi’s Laboratories remains a key player in the pharmaceutical sector, benefiting from investor optimism driven by robust fundamentals and industry outlook.

Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. The author or Business Upturn is not liable for any losses arising from the use of this information.

Divi’s Laboratories surge nearly 2% as Citi reiterates bullish stance

Aditya Bhagchandani — Fri, 29 Nov 2024 04:05:18 +0000

Shares of Divi’s Laboratories Ltd. rose nearly 2% on November 29 after international brokerage Citi reaffirmed its ‘buy’ call on the stock, naming it as the top pick in the Indian pharma sector. Citi highlighted the company’s expanding pipeline for its contrast media business as a key driver for future growth and set a price target of ₹6,850, indicating a potential upside of 15% from Thursday’s closing price.

Key Drivers:

Expanding Pipeline: Divi’s Labs is focusing on building a strong pipeline in the contrast media segment, a crucial area in medical imaging.
USFDA Ruling on Entresto: The US court’s decision to stay the United States Food and Drug Administration’s approval of a generic version of Novartis AG’s blockbuster heart failure drug, Entresto, has brought relief. This ruling reduces competitive pressures on sales of the drug Divi’s manufactures for Novartis.

Market Performance:

As of 9:34 am, Divi’s shares were trading 1.47% higher at ₹6,039.00 on the NSE.

Divi’s Laboratories market cap gains Rs 1,806 crore – Know More

Aditya Bhagchandani — Thu, 21 Nov 2024 05:24:44 +0000

Shares of Divi’s Laboratories surged 1.15% today, closing at Rs 5,968.75. This upward movement resulted in a market cap increase of approximately Rs 1,806 crore, bringing the total market capitalization to Rs 1,58,451.56 crore.

Key Trading Highlights:

Previous Close: Rs 5,900.85
Closing Price: Rs 5,968.75
Market Cap Increase: Rs 1,806 crore
Current Market Cap: Rs 1,58,451.56 crore

Price and Volume Details:

Opening Price: Rs 5,880.10
Intraday High: Rs 6,004.50
Intraday Low: Rs 5,880.10
Volume Traded: 2.09 lakh shares
Turnover: Rs 124.26 crore

52-Week Performance:

52-Week High: Rs 6,275.85 (October 15, 2024)
52-Week Low: Rs 3,350.00 (March 27, 2024)

Divi’s Laboratories continues to gain investor confidence, supported by robust fundamentals and consistent performance in the pharmaceutical sector.

Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. The author or platform is not liable for any losses arising from the use of this information.

Divi’s Laboratories’ market cap surges by Rs 3,534 crore today – Know More

Aditya Bhagchandani — Tue, 19 Nov 2024 06:17:14 +0000

Shares of Divi’s Laboratories Limited rose by 2.31% today, closing at Rs 5,900. This rise contributed to a significant market cap gain of Rs 3,534 crore, pushing the company’s total market capitalization to Rs 1,56,626.46 crore.

Key Trading Details:

Previous Close: Rs 5,766.65
Today’s High: Rs 5,900.05
Today’s Low: Rs 5,769.85
Traded Volume: 1.37 lakh shares
Traded Value: Rs 80.01 crore

52-Week Performance:

52-Week High: Rs 6,275.85 (October 15, 2024)
52-Week Low: Rs 3,350.00 (March 27, 2024)

The pharmaceutical giant continues to demonstrate resilience in the market, benefiting from strong investor confidence and consistent performance within the healthcare sector.

Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. The author or Business Upturn is not liable for any losses arising from the use of this information.

Divi’s Laboratories shares in focus following Q2 results

Aditya Bhagchandani — Mon, 11 Nov 2024 04:25:19 +0000

Divi’s Laboratories reported a robust 46.6% year-on-year increase in profit after tax (PAT) for Q2 FY25, reaching ₹510 crore, driven by growth in its custom synthesis business. The company saw increased demand from both existing and new customers in this segment. In comparison, PAT stood at ₹348 crore in the same quarter last year.

As of 9:55 am the shares were trading 0.35% lower at ₹5,928.95 on NSE

Key Financial Highlights

Revenue: Revenue for the quarter rose 22.5% to ₹2,444 crore, up from ₹1,995 crore in Q2 FY24. Approximately 87% of this revenue came from exports, with the US and Europe together contributing around 71%.
Forex Gains: Divi’s Laboratories recorded a forex gain of ₹29 crore in Q2 FY25, compared to a gain of ₹11 crore in Q2 FY24.
EBITDA: The company’s EBITDA came in at ₹716 crore, surpassing analyst expectations of ₹670 crore.
Operating Profit Margin: The operating profit margin improved by 600 basis points year-over-year, reaching 31%.
Business Composition: The generic business constitutes 49% of the company’s revenue, while the remainder comes from custom synthesis and nutraceuticals. Divi’s noted ongoing pricing pressure in the generic segment.

With ₹3,602 crore in cash reserves, Divi’s Laboratories continues to maintain a strong financial position.

Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.

Divi’s Laboratories Q2 FY25 Results: Revenue grows 22.47% YoY to ₹2,338 crore, Net Profit up 46% YoY

Aditya Bhagchandani — Sat, 09 Nov 2024 07:18:40 +0000

Divi’s Laboratories announced its financial results for the quarter ending September 30, 2024, showing impressive growth across key metrics. The pharmaceutical major reported a revenue from operations of ₹2,338 crore, marking a year-on-year (YoY) increase of 22.47% compared to ₹1,909 crore in the corresponding quarter last year. The revenue also saw a quarter-on-quarter (QoQ) rise of 10.39% from ₹2,118 crore in Q1 FY25.

The company’s net profit for Q2 FY25 came in at ₹510 crore, representing a significant 46.55% YoY growth compared to ₹348 crore in the same quarter of the previous year. This growth also reflects an 18.6% increase over the net profit of ₹430 crore reported in Q1 FY25.

For the half-year period ending September 30, 2024, Divi’s Laboratories achieved a consolidated total income of ₹4,640 crore, a 20.38% increase from ₹3,854 crore in the same period last year. The half-year PBT rose to ₹1,326 crore, compared to ₹961 crore in the previous year, while PAT reached ₹940 crore, up from ₹704 crore for the same period.

The robust growth in both revenue and profit for Divi’s Laboratories highlights strong performance in the company’s operations, reinforcing its position in the pharmaceutical sector. The company has attributed this growth to better operational efficiencies and improved market conditions.

Divi’s Laboratories share price today: 0.21% up at ₹6,129.30

Aditya Bhagchandani — Mon, 14 Oct 2024 04:57:17 +0000

Divi’s Laboratories shares were trading 0.21% lower at ₹6,129.30 today, hoping for a more optimistic outlook for the company’s growth. This comes after the drugmaker recently exited from the Nifty 50 index, but some analysts are seeing renewed potential in the company’s pipeline and market position.

Much of this renewed growth outlook revolves around Divi’s opportunity in the GLP-1 API (Glucagon-Like Peptide-1 Active Pharmaceutical Ingredients) segment. GLP-1 APIs are crucial in treatments for type 2 diabetes and obesity, regulating blood sugar levels and enhancing insulin secretion. This emerging pharmaceutical segment presents a significant revenue opportunity for Divi’s Laboratories as global innovators look to de-risk supply chains.

Brokerage firm Citi recently re-initiated coverage of Divi’s Labs with a ‘buy’ rating, citing the company’s secured position in the GLP-1 API market. Citi estimates this could bring over $800 million in revenue potential by 2030 for Divi’s, solidifying its place in the global pharmaceutical supply chain.

Though the stock has seen some downward pressure in recent months, analysts are warming up to the company’s growth potential in the long term, especially with its presence in the critical GLP-1 API space.

Divi’s Laboratories shares surge 5% after strong Q4 results

Aditya Bhagchandani — Mon, 27 May 2024 04:43:23 +0000

Divi’s Laboratories saw a significant rise in its share price, gaining 5% in morning trades on Monday following the announcement of its Q4 results over the weekend.

The company’s consolidated net profit showed a 68% year-on-year increase, reaching Rs 538 crore compared to Rs 321 crore in the same quarter last year. This result surpassed Zee Business research desk’s estimate of Rs 427 crore.

Divi’s Laboratories reported revenue of Rs 2,303 crore, beating the estimated Rs 2,058 crore. This marks an 18% year-on-year increase from Rs 1,951 crore in the previous year. Additionally, the company’s EBITDA saw a substantial 50% year-on-year growth, reaching Rs 731 crore, up from Rs 487 crore in the same period last fiscal year.

As of 10:10 am, the shares were trading 4.50% higher at ₹4,307.75 on the NSE.